International Joint Sessions at SOLACI-SBHCI 2023

The most important Scientific Societies in the world will be present at the SOLACI-SBHCI 2023 Congress. Discover them below.



Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

 

More articles by this author

SOLACI-SBHCI 2023 | AORTIC ANEURYSM FROM THE GUIDELINES TO THE REAL WORLD – Dr. Felix Damas de los Santos

Read the most outstanding articles from SOLACI-SBHCI 2023 Congress. In this case, check the presentation by Dr. Felix Damas de los Santos, entitled “Alternative Vascular...

SOLACI-SBHCI 2023 Scientific Coverage – Day 3

The third day of the Congress started at the Copacabana Arena with the International Live Case held at Nanjing First Hospital, Nanjing, China, which...

The former presidents of SOLACI and SBHCI received their well-deserved tribute during the SOLACI-SBHCI 2023 Congress

During the SOLACI-SBHCI 2023 Congress, a special session was held to honor the great figures of interventional cardiology in Brazil and Latin America, whose...

SOLACI Research Registries were presented at the SOLACI-SBHCI 2023 Congress

The area of records within SOLACI - SOLACI Research - continues to grow and share the results of its investigations with the entire Latin...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...